Tina Williamson, Director of Corporate Compliance for Mississippi Children’s Home Services, shares tips and advice for those transitioning from the clinical field into healthcare compliance; namely, leveraging clinical experience for compliance success.
According to Matt Vogelien, New York’s Mandatory Medicaid Compliance Program requirements represent a significant step in the potential transition toward mandatory compliance programs for healthcare organizations.
Collen Faddick and Gina Kastel from Faegre & Benson discuss specific examples of enhanced transparency expectations and the factors that contribute to them, and conclude with suggestions for compliance professionals to adapt to these changes.
Morgan Ryan of Dallas-based insurance agency SIG Insurance Professionals provides a few key points regarding compliance with the recently passed health care reform bill.
On Christmas Eve it was announced that Boston Scientific has agreed to pay $22 million as it settles claims that one of its divisions gave kickbacks to doctors.
Wendy Wysong, partner at Clifford Chance US LLP, discusses why health care providers should be critically reviewing their longstanding financial relationships to ensure compliance with recent revisions to the Stark and the Anti-Kickback laws.
Eric McClafferty, export compliance and international trade regulation partner at Kelley Drye & Warren LLP, examines important FCPA compliance and export compliance keys for health industry companies.
By Joel Hesch, Liberty University
The government has honed in on three primary areas where it alleges that a pharmaceutical company commits fraud. In addition, there is an emerging new area, adulterated products, where the DOJ is beginning to investigate and just may be the next huge compliance risk.
In today’s GRC news roundup, we link out to a story on health care organizations being to told to update anti-fraud compliance programs as well as the resurfacing a few now-notorious former Lehman execs, among others.
In today’s roundup, we offer links to the recent approval by Wyeth shareholders of the Pfizer takeover, corporate governance in times of crisis, and Andrew Cuomo’s intentions to sue Schwab for fraud over ARS.
